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Abstract Multiple endocrine neoplasia type 1 (MEN1) is
a hereditary syndrome associated with the development of
many endocrine tumors, involving mainly pituitary, para-
thyroids, pancreas, although a proliferative state interests
all neuroendocrine system. MEN1 pancreatic neuroendo-
crine tumors (pNETs) are multiples and can secrete dif-
ferent hormones. The therapeutic approach is based on
surgery which usually is followed by tumor relapse or
persistence unless to be highly aggressive. Biotherapy with
somatostatin analogs and dopamine agonists could be of
great benefit to manage these patients without altering
their life quality. We report a case of a 36-year-old MEN1
man affected with multicentric pNETs associated with
insulinoma syndrome. Therapy with symptomatic agents
(diazoxide), as well as biotherapy (lanreotide, cabergoline)
was started. At 6-month follow-up, symptomatic agents
were stopped and disease control was only based on lan-
reotide plus cabergoline. This combined biotherapy was
able to control endocrine syndromes and tumor growth.
Subsequently, a safer and selective surgical intervention
on pNETs was performed. An excellent response to ther-
apy with lanreotide autogel and cabergoline has been
observed in a MEN1 patient with pNETs associated with
insulinoma syndrome. The potential synergistic effects of
lanreotide autogel and cabergoline on insulin-secreting
neuroendocrine tumors are discussed.
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Introduction
Multiple endocrine neoplasia type 1 (MEN1) is a heredi-
tary syndrome predisposing to the development of many
endocrine and neuroendocrine tumors (NETs) and/or
hyperplasia, involving mainly pituitary, parathyroids, and
pancreas [1]. In these patients, prognosis is mainly related
to the behavior of tumors arising from pancreas [2]. Pan-
creatic NET (pNET) arising from islet cells may be non-
functioning or functioning, with production of active
hormones such as gastrin, insulin, vasoactive intestinal
polypeptide, glucagon, and somatostatin [3]. Therapeutic
approach in pNETs is based on surgery. However, in
MEN1 there is a high risk of recurrence even after radical
surgery and a considerable risk of morbidity and mortality
associated with the surgical management [4, 5].
Somatostatin analogs (SSAs) have been demonstrated to
induce symptomatic, biochemical, and antiproliferative
effects in well-differentiated NETs [6, 7]. Unfortunately,
neither sub-cutaneous nor long-acting slow release SSAs
resulted in high rate of clinical and biochemical response in
patients with insulin-secreting pNETs [8, 9]. Furthermore,
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response duration is variable and side effects such as a
paradoxical impairment of hypoglycemia, due to predom-
inant suppression of contraregulator hormones, may occur
[9, 10].
Dopamine agonists (DAs) are effective in controlling
tumor growth and hormone secretion in pituitary tumors.
DA activity in NETs is hypothesized on the basis of
reported expression of dopamine receptors (DR2) in these
tumors. Possible synergistic effects of SSAs and DAs could
be of great benefit to manage MEN1-related pNETs, either
arresting tumor growth or maintaining their unaltered
quality of life.
In this case report, we describe a MEN1 man affected by
multiple insulin-secreting and nonfunctioning pNETs
experiencing an excellent response to the treatment with
lanreotide autogel, a long-acting formulation of SSA. Since
a concomitant therapy with cabergoline was given for a
prolactin (PRL)-secreting pituitary adenoma, the potential
synergistic effects of lanreotide autogel and cabergoline on
insulinoma are discussed.
Case presentation
A 36-year-old man presented with symptoms of neuroglyco-
paenia. Physical examination revealed sweating and tachy-
cardia. Biochemical assessment showed hypoglycemia and
not suppressed insulin and C-peptide levels (Fig. 1). Fasting
test confirmed the clinical diagnosis of insulinoma by
revealing an insulin to glycaemia ratio of 0.6 and C-peptide
serum concentrations of 6.0 ng/ml in condition of hypogly-
cemia. To localize the insulin-secreting primary tumor, a
contrast-enhanced helical computed tomography (CT) was
performed and detected 4 nodules ranging 10–25 mm along
head, body, and tail of the pancreas. A complete hormonal and
instrumental work-up was performed to characterize the
pNETs and to screen for a MEN1 syndrome. High plasma
levels of chromogranin A (not shown) and gastrin
([150 pmol/l) were found and associated, at the endoscopy, to
an erosive gastro-duodenitis. A pituitary microadenoma was
detected by magnetic resonance imaging and characterized by
PRL hypersecretion ([3,000 mU/l), while primary hyper-
parathyroidism (PTH = 15.8 pmol/l) with a mild increase of
serum calcium levels (2.6 mmol/l) was associated to a left
inferior parathyroid adenoma at cervical Doppler ultraso-
nography and sestamibi SPECT scintigraphy. A whole body
Indium-111-DTPA-Phe1-octreotide scintigraphy (Octreo-
scan) pointed out a strong uptake corresponding to the greatest
pancreatic lesion.
The diagnosis of insulinoma syndrome, Zollinger–Elli-
son syndrome, microprolactinoma, and primary hyper-
parathyroidism was made. This picture was consistent with
the diagnosis of MEN1 syndrome. To confirm the diag-
nosis of MEN1, germline mutation in the menin gene was
searched as previously described [11]. A novel heterozy-
gote frameshift 335delA mutation in the exon 2 was
revealed in this patient.
In order to control the Zollinger–Ellison syndrome,
proton pump inhibitor (omeprazole) was prescribed (20 mg
twice a day) followed by a rapid improvement of gastric
symptoms. One week later, diazoxide (300 mg a day in 3
daily doses) and lanreotide (slow release formulation,
30 mg every 2 weeks) were introduced in the schedule
treatment, in order to improve symptoms related to
hyperinsulinemia the former and to inhibit gastrin and
insulin hypersecretion the latter. A high hydratation regi-
men plus hydrochlorothiazide (25 mg a day) was recom-
mended to achieve normocalcemia. During the first
3 months of therapy, a decrease of frequency and severity
of hypoglycemic events occurred. At the 3-month hor-
monal follow-up, normalization of gastrin (\25 pmol/l), as
well as marked decrease of C-peptide (Fig. 1) with nor-
malization of the insulin to glycemia ratio was observed.
No side effects were observed. Therefore, omeprazole
treatment was stopped, diazoxide treatment was lowered
(150 mg a day divided in 3 daily doses) and lanreotide was
given at the dose of 60 mg every 4 weeks. Due to the
progressive increase of PRL levels ([4,000 mU/l), a ca-
bergoline schedule treatment was started. At 6-month fol-
low-up, a stable normalization of gastrin levels, a further
Fig. 1 Hormonal markers of insulinoma (serum glycaemia, insulin, and C-peptide) before and 3, 6, and 12 months after the beginning of
treatment. Lanreotide treatment was started at basal, while cabergoline was started at 3 month
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decrease of insulin and C-peptide (Fig. 1) and a suppres-
sion of PRL levels were observed, allowing to stop diaz-
oxide and to decrease cabergoline doses. At this time,
lanreotide autogel 120 mg every 8 weeks was started in
place of lanreotide 60 mg every 4 weeks. This hormonal
picture remains unchanged at the 12-month follow-up
(Fig. 1). These results paralleled the complete disappear-
ance of hypoglycemic events and gastrointestinal disorders.
A morphological evaluation of the pNETs was performed
1 year after the beginning of the treatment: compared to
basal CT scan, the nodules were stable in size and number.
Contrast enhancement of the pNETs, which was high and
rapid at baseline, was then scarce after medical therapy.
Due to the complete and stable normalization of
symptomatology, as well as the possibility to completely
remove pNETs, the patient underwent distal pancreatec-
tomy, tumor enucleation in the pancreatic head and duo-
denum and locoregional lymph node dissection. Histology
and immunohistochemistry for chromogranin A and syn-
aptophysin highlighted a diagnosis of well-differentiated
pNET (G1) in a total of 16 nodules (size ranging
3–22 mm). Two insulin-positive pNETs were found in
pancreas, while a gastrin-positive tumor was found in
duodenum. All lymph nodes were unaffected.
After surgery, the patient recovered rapidly and was
discharged without any therapy but cabergoline. Both basal
and secretin-stimulated pancreatic hormone values were
normal, and neither clinical symptoms nor tumor recur-
rence was after a 5 year follow-up.
Discussion
Surgery represents the treatment of choice for MEN1-
related pNETs with significant benefits in terms of survival.
However, this approach for small tumors is still contro-
versial because pNETs \ 2 cm seem to have a more
indolent behavior. In particular, pNET surgery in MEN1 is
associated with a higher risk of complications and mor-
tality, as well as a high rate of recurrence [5].
SSAs represent the gold standard in the treatment of
functioning NETs [9]. The PROMID study demonstrated
also that octreotide LAR has antiproliferative effects in
patients with metastatic NETs of midgut, significantly
improving the time to progression as compared to placebo
[7]. However, in insulin-secreting pNET, SSAs seem to
difficultly control hormone secretion and proliferating
activity [12]. In fact, even if SSAs inhibit insulin secretion
and activity [13, 14], the SSA-induced inhibition of contra-
regulatory hormones (glucagon, GH, and IGF-1) may be
higher than insulin suppression, resulting in scarce effec-
tiveness in the improvement of hypoglycemia [15]. The
inadequate control of insulin secretion by SSAs is likely a
consequence of the low expression of SSTR2 and SSTR5
in insulin-secreting pNET, which also explains the low
percentage of Octreoscan-positive tumors.
In the current case, a MEN1 patient with multiple pNETs
associated with Zollinger–Ellison and insulinoma syndrome,
after an initial clinical improvement on SSA, experienced a
complete and stable clinical remission on SSA and DA
therapy. At CT scan, pNETs were stable, while contrast
enhancement was decreased revealing decreased tumor
activity [16]. These findings could be imputable to the
combined use of biotherapy with SSA and DA, even if it is
difficult to exclude that only one of the two drugs was active.
In this regard, it was previously reported in literature a case
of a patient affected by prolactinoma and metastatic islet cell
tumor secreting pancreatic polypeptide (PP), where DAs
caused a decrease in PP levels and inhibited liver metastases
[17]. Double-staining experiments showed that D2 colocal-
ized with insulin-containing secretory granules and quinpi-
role, a D2-like receptor agonist, was able to inhibit glucose-
stimulated insulin secretion, suggesting a potential impli-
cation of D2 on this activity [18]. Besides, it has been
demonstrated that D2 are expressed in NET associated with
ectopic ACTH syndrome and that cabergoline may be
effective in controlling cortisol excess in a subgroup of these
patients [19]. In NETs, D2 is frequently expressed in low-
and intermediate-grade tumors, but it is to underlined that, in
the majority of cases, it is coexpressed with SSTR2 and
SSTR5 [20–22]. However, the in vivo efficacy of DA has not
well-established yet in NET [22]. In the last years, basic
research observations on the interaction of SSTR and DR2,
and clinical reports of efficacy of combined SST and DA
treatment in pituitary adenomas [23, 24], lead to the concept
of creating chimeric molecules combining structural features
of both compound classes. SSTR/DR2 chimeric compounds
have recently been investigated also in NETs resulting in
decreased cell viability in human midgut NET cells [25].
In conclusions, a combined therapy with SSA and DA
was associated with complete normalization of a hype-
rinsulinemic hypoglycemia syndrome and tumor stabiliza-
tion in a patient with MEN1 pNETs. In patients with
insulinoma, particularly if associated with MEN1, SSA,
and DA should be taken in account not only to normalize
the functional syndrome but also to induce antitumoral
effects.
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